Expeditors International of Washington just posted its biggest single-day gain in months, yet the options market is more defensive than it has been all year.
The price tells the obvious story first. EXPD jumped 9.6% on May 5 to close at $153.08, following its Q1 earnings release. The stock is up 3.9% on the week and 5% over the past month — a strong run for a name the Street has largely kept on Hold. What makes the setup interesting heading into the aftermath is that options positioning spiked sharply on the day of that rally, not before it, raising the question of whether traders are hedging a move that has already happened or pricing in further turbulence ahead.
The clearest post-print signal comes from the options market. The put/call ratio jumped to 0.30 on May 5, more than two standard deviations above its 20-day average of 0.23. That's the most defensive reading in the context of recent months, even as the stock rallied hard. For comparison, the PCR spent most of April in a tight 0.20–0.24 band. The sudden divergence — call volume still dominates at 0.30, but the put side surged relative to trend — suggests at least a cohort of traders are buying downside protection into the new price level.
Short interest, by contrast, has been easing. The February peak in SI % of free float sat near 3.9% in late April; it has since unwound back to 3.5% as of May 5. That decline tracks the stock's recovery — shorts covered through the rally, rather than pressing the position. Borrowing costs remain modest at 0.48%, up about 13% on the week but barely above the 0.40%–0.53% range that has held since March. Borrow availability is extremely loose, with lending pool utilization running near 5% against a 52-week high of 11.9%, meaning there is no structural squeeze pressure at current levels.
The Street remains cautious despite the pop. The analyst consensus clusters around Hold or Neutral, with the mean price target at $145.07 — roughly 5% below where the stock now trades after earnings. The most recent action came today: Susquehanna raised its target to $156 from $142 while maintaining Neutral, an acknowledgment of the earnings beat but not a ringing endorsement of the valuation. Earlier in the year, JPMorgan and Barclays both carried Underweight ratings; Morgan Stanley's target, raised to $95 in December, looks markedly out of step with current levels and should be treated as dated. On valuation, the P/E is running near 22.8x and EV/EBITDA at 16.4x — both expanding on the week as the price outpaced any earnings revision. Factor scores are constructive on EPS momentum (86th percentile on the 30-day measure, 85th on surprise), but the overall ORTEX short score of 36.6 is unremarkable, ranking near the middle of the universe.
One piece of background context worth noting: a cluster of insider sales landed on May 1, just ahead of the earnings print. CEO Daniel Wall sold 661 shares at $147.89, the General Counsel sold 313 shares, and division president Blake Bell sold 1,115 shares alongside receiving a stock award. The transactions were all small in absolute dollar terms — combined well under $400,000 — and carried the lowest significance score, suggesting routine plan-driven activity rather than a conviction signal. On a 90-day net basis, insiders are actually net buyers, with $4.8 million in net value purchased.
The February earnings print offers the only useful reference point in the data. EXPD fell 5.2% the day after that release and recovered only partially over the following week, finishing five days later down 1.1%. The Q1 result has clearly landed better. What to watch next: whether the stock can hold above the analyst consensus target of $145 — now trading at a premium to most Street estimates — and how the put/call ratio evolves once the immediate post-earnings positioning clears ahead of the next report in early August.
See the live data behind this article on ORTEX.
Open EXPD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
